Keyphrases
Virus
100%
Immunogenicity
100%
Modified-live Virus Vaccine
100%
Granulocyte Colony-stimulating Factor (G-CSF)
50%
Immunization
33%
Virus-specific
33%
Primates
33%
Bovine Parainfluenza Virus Type 3 (BPIV3)
33%
T Cells
16%
Serum Antibody
16%
Antibody Response
16%
Complementary DNA (cDNA)
16%
Monkey
16%
Viral Replication
16%
Live Attenuated
16%
Etiological Agents
16%
Vaccine Candidate
16%
Virus Replication
16%
Live Attenuated Vaccine
16%
Vaccine Virus
16%
Viral Disease
16%
Immunogenic
16%
Next-generation Vaccines
16%
Dengue
16%
Respiratory Syncytial Virus
16%
Peripheral Blood
16%
Rhesus Monkey
16%
Influenza
16%
Live Attenuated Vaccine Candidate
16%
Parainfluenza
16%
Improved Vaccines
16%
Topical Administration
16%
Recombinant Virus
16%
Respiratory Symptoms
16%
Enveloped RNA Viruses
16%
Attenuated Virus
16%
Measles
16%
Pediatric Pulmonary
16%
Mortality Burden
16%
Equal Length
16%
Morbidity Burden
16%
Immunology and Microbiology
Immunogenicity
100%
Attenuated Vaccine
100%
Live Vaccine
100%
Virus
100%
Granulocyte Macrophage Colony-Stimulating Factor
33%
Viral Replication
22%
Human Parainfluenza Virus 3
22%
Ribonucleic Acid
22%
Antibody Response
11%
Viral Disease
11%
T Cell
11%
Antibody Blood Level
11%
RNA Virus
11%
Influenza
11%
Human Respiratory Syncytial Virus
11%
Rhesus Monkey
11%
Dengue Fever
11%
Parainfluenza
11%
Measles
11%
Recombinant Virus
11%
Virus Attenuation
11%